Altea Therapeutics

Altea Therapeutics has made a key scientific and commercial breakthrough in the delivery of drugs and vaccines via the skin. The PassPort® patch, a cost-effective and easy to use skin patch, uses short bursts of focused thermal energy to create hundreds of tiny channels in the surface of the skin. These channels permit the rapid and sustained flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. Altea Therapeutics is a privately-held company, with Domain Associates, Venrock Associates, vSpring Capital, KBC Investco, Aperture Venture Partners, Quilvest, CX BioVentures, and Rockport Venture Partners as primary investors. Our intellectual property portfolio includes over 30 issued patents (U.S. and foreign) and provides comprehensive protection for our pipeline products to at least 2020.